Ian S Hagemann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4241986/publications.pdf

Version: 2024-02-01

86 4,677 26 66 papers citations h-index g-index

92 92 92 92 9050

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women. Fetal and Pediatric Pathology, 2022, 41, 403-412.	0.4	28
2	Advancing Fellowship Training in Selective Pathology. Archives of Pathology and Laboratory Medicine, 2022, 146, 501-506.	1.2	0
3	GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. Molecular Cancer Research, 2022, 20, 265-279.	1.5	19
4	Prospective Assessment of Adjunctive Ultrasound-Guided Diffuse Optical Tomography in Women Undergoing Breast Biopsy: Impact on BI-RADS Assessments. , 2022, , .		0
5	Identification of novel ALK rearrangements in gynecologic clear cell carcinoma. International Journal of Cancer, 2021, 148, 459-468.	2.3	5
6	Pathologist Concordance for Ovarian Carcinoma Subtype Classification and Identification of Relevant Histologic Features Using Microscope and Whole Slide Imaging. Archives of Pathology and Laboratory Medicine, 2021, 145, 1516-1525.	1.2	5
7	In-laboratory breast specimen radiography reduces tissue block utilization and improves turnaround time of pathologic examination. BMC Medical Imaging, 2021, 21, 59.	1.4	3
8	The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecologic Oncology, 2021, 160, 660-668.	0.6	9
9	Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography. Breast Cancer Research and Treatment, 2021, 188, 615-630.	1.1	8
10	ImmunogenomicÂprofiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 189, 187-202.	1.1	24
11	Retroperitoneal Dedifferentiated Liposarcoma. American Journal of Clinical Pathology, 2021, 156, 920-925.	0.4	7
12	Molecular Testing in Breast Cancer. Journal of Molecular Diagnostics, 2021, 23, 1422-1432.	1.2	14
13	Malignant Phyllodes Tumor: Imaging Features With Histopathologic Correlation. Journal of Breast Imaging, 2021, 3, 703-711.	0.5	5
14	GAS6 inhibition induces platinum sensitivity through increased replication stress in ovarian cancer. Gynecologic Oncology, 2021, 162, S40.	0.6	0
15	OUP accepted manuscript. Clinical Chemistry, 2021, , .	1.5	О
16	Prospective assessment of adjunctive ultrasound-guided diffuse optical tomography in women undergoing breast biopsy: Impact on BI-RADS assessments. European Journal of Radiology, 2021, 145, 110029.	1.2	5
17	Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer. Medical Oncology, 2020, 37, 12.	1.2	5
18	Clinical Decision Support for Ovarian Carcinoma Subtype Classification: A Pilot Observer Study With Pathology Trainees. Archives of Pathology and Laboratory Medicine, 2020, 144, 869-877.	1.2	7

#	Article	IF	Citations
19	Sequence Now, Later, or Never?. Clinical Chemistry, 2020, 66, 883-885.	1.5	O
20	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152.	3.2	163
21	Detection of a somatic GREB1-NCOA1 gene fusion in a uterine tumor resembling ovarian sex cord tumor (UTROSCT). Gynecologic Oncology Reports, 2020, 34, 100636.	0.3	10
22	Pathologic findings in fallopian tubes of women with chronic pelvic pain after Essure placement. Contraception, 2020, 102, 133-136.	0.8	2
23	Histogram analysis of en face scattering coefficient map predicts malignancy in human ovarian tissue. Journal of Biophotonics, 2019, 12, e201900115.	1.1	11
24	Optical Resolution Photoacoustic Microscopy of Ovary and Fallopian Tube. Scientific Reports, 2019, 9, 14306.	1.6	17
25	Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 389-398.	1.9	32
26	Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. Gynecologic Oncology Reports, 2018, 23, 16-19.	0.3	2
27	p16 Immunohistochemistry Is Not Always Required For Accurate Diagnosis of Grade 2 Squamous Intraepithelial Lesions. Journal of Lower Genital Tract Disease, 2018, 22, 104-109.	0.9	2
28	Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair. International Journal of Gynecological Pathology, 2018, 37, 581-589.	0.9	4
29	Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid Gland Associated with Amyloid Goiter: A Medullary Thyroid Carcinoma Mimic on Intra-operative Frozen Section. Head and Neck Pathology, 2018, 12, 269-273.	1.3	5
30	Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US. Radiology, 2018, 289, 740-747.	3.6	60
31	Quantitative multispectral ex vivo optical evaluation of human ovarian tissue using spatial frequency domain imaging. Biomedical Optics Express, 2018, 9, 2451.	1.5	12
32	Maternal obesogenic diet induces endometrial hyperplasia, an early hallmark of endometrial cancer, in a diethylstilbestrol mouse model. PLoS ONE, 2018, 13, e0186390.	1.1	6
33	3D visualization of the ovarian tissue scattering coefficient with swept-source optical coherence tomography. , 2018, , .		0
34	Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing. Experimental and Molecular Pathology, 2017, 102, 156-161.	0.9	37
35	Osteolipoma of the knee. Radiology Case Reports, 2017, 12, 124-129.	0.2	6
36	Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia, 2017, 19, 100-111.	2.3	27

#	Article	IF	CITATIONS
37	Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix. International Journal of Gynecological Pathology, 2017, 36, 593-599.	0.9	15
38	Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity. Cancer Immunology Research, 2017, 5, 516-523.	1.6	74
39	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. Molecular Cancer Therapeutics, 2017, 16, 2881-2891.	1.9	27
40	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	3.2	66
41	Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report. Gynecologic Oncology Reports, 2017, 20, 121-124.	0.3	10
42	Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC) Journal of Clinical Oncology, 2017, 35, 6012-6012.	0.8	62
43	Increased breast tissue receptor activator of nuclear factor- \hat{P} B ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. Oncotarget, 2017, 8, 73787-73792.	0.8	12
44	Abstract 3847: Oral cavity squamous cell carcinoma xenografts display conservation of primary tumor genomic heterogeneity. , 2017, , .		0
45	A common founding clone with <i>TP53</i> and <i>PTEN</i> mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia. Journal of Physical Education and Sports Management, 2016, 2, a000687.	0.5	15
46	Molecular Testing in Breast Cancer: A Guide to Current Practices. Archives of Pathology and Laboratory Medicine, 2016, 140, 815-824.	1.2	43
47	Clinical Outcomes among Women with Mucinous Adenocarcinoma of the Ovary. Gynecologic and Obstetric Investigation, 2016, 81, 411-415.	0.7	10
48	AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget, 2016, 7, 77291-77305.	0.8	26
49	Optimal Sampling of Grossly Normal Omentum in Staging of Gynecologic Malignancies. International Journal of Gynecological Pathology, 2015, 34, 281-287.	0.9	13
50	Seminoma Presenting as Renal Mass, Inferior Vena Caval Thrombus, and Regressed Testicular Mass. Case Reports in Urology, 2015, 2015, 1-4.	0.1	1
51	The Cancer Genomics Resource List 2014. Archives of Pathology and Laboratory Medicine, 2015, 139, 989-1008.	1.2	18
52	Diagnostic yield of targeted next generation sequencing in various cancer types: An information-theoretic approach. Cancer Genetics, 2015, 208, 441-447.	0.2	9
53	T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. Journal of the American Academy of Dermatology, 2015, 73, 228-236.e2.	0.6	76
54	Molecular Pathology of Hereditary and Sporadic Medullary Thyroid Carcinomas. American Journal of Clinical Pathology, 2015, 143, 768-777.	0.4	36

#	Article	IF	Citations
55	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research, 2015, 21, 2840-2850.	3.2	52
56	Clinical nextâ€generation sequencing in patients with non–small cell lung cancer. Cancer, 2015, 121, 631-639.	2.0	190
57	Overview of Technical Aspects and Chemistries of Next-Generation Sequencing., 2015,, 3-19.		17
58	Abstract LB-109: Exome sequencing identifies common somatic mutations in an adult patient with a concurrent germ cell tumor (GCT) and acute myeloid leukemia (AML) suggesting a single clonal origin. , 2015, , .		0
59	Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. BMC Genomics, 2014, 15, 868.	1.2	49
60	Diagnostic Utility of Targeted Next-generation Sequencing in Problematic Cases. American Journal of Surgical Pathology, 2014, 38, 534-541.	2.1	16
61	Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nature Medicine, 2014, 20, 607-615.	15.2	742
62	Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology. Journal of Molecular Diagnostics, 2014, 16, 89-105.	1.2	168
63	Stabilization of Disease after Targeted Therapy in a Thymic Carcinoma with KIT Mutation Detected by Clinical Next-Generation Sequencing. Journal of Thoracic Oncology, 2014, 9, e12-e16.	0.5	20
64	Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. Cancer Genetics, 2013, 206, 420-431.	0.2	50
65	Mammaglobin expression in gynecologic adenocarcinomas. Human Pathology, 2013, 44, 628-635.	1.1	21
66	Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecologic Oncology, 2013, 128, 83-87.	0.6	21
67	Abstract 3968: Ovarian cancer chemokine microenvironment is conducive to homing of CD3/CD28 co-stimulated T cells prepared for adoptive transfer therapy , 2013, , .		0
68	Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. Molecular Therapy, 2012, 20, 633-643.	3.7	161
69	Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels. PLoS ONE, 2012, 7, e49829.	1.1	60
70	Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2012, 124, 192-198.	0.6	527
71	Aberrant connexin 43 and 26 expression in cervical dysplasia. , 2012, 34, 28-40.		0
72	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature, 2011, 475, 226-230.	13.7	1,071

#	Article	IF	CITATIONS
73	Risk of Occult Malignancy in Morcellated Hysterectomy. International Journal of Gynecological Pathology, 2011, 30, 476-483.	0.9	58
74	Tissue-based immune monitoring II. Cancer Biology and Therapy, 2011, 12, 367-377.	1.5	21
75	Tissue-based immune monitoring I. Cancer Biology and Therapy, 2011, 12, 357-366.	1.5	10
76	High-throughput detection of prostate cancer in histological sections using probabilistic pairwise Markov models. Medical Image Analysis, 2010, 14, 617-629.	7.0	107
77	A Retrospective Comparison of 2 Methods of Intraoperative Margin Evaluation During Partial Nephrectomy. Journal of Urology, 2009, 181, 500-505.	0.2	31
78	Structure of the Complement Factor 5a Receptor-Ligand Complex Studied by Disulfide Trapping and Molecular Modeling. Journal of Biological Chemistry, 2008, 283, 7763-7775.	1.6	25
79	Basaloid Squamous Cell Carcinoma Arising of the Renal Pelvis. International Journal of Surgical Pathology, 2008, 16, 199-201.	0.4	4
80	E2F8 is a nonreceptor activator of heterotrimeric G proteins. Journal of Molecular Signaling, 2007, 2, 3.	0.5	6
81	A careful look at community CPR training. Missouri Medicine, 2007, 104, 481-4.	0.3	0
82	Synthesis, structure and physical properties of Ru ferrites: BaMRu5O11 (M=Li and Cu) and BaM′2Ru4O11 (M′=Mn, Fe and Co). Journal of Solid State Chemistry, 2006, 179, 563-572.	1.4	53
83	Comparison of the retinitis pigmentosa mutations in rhodopsin with a functional map of the C5a receptor. Vision Research, 2006, 46, 4519-4531.	0.7	4
84	Random Mutagenesis of the Complement Factor 5a (C5a) Receptor N Terminus Provides a Structural Constraint for C5a Docking. Journal of Biological Chemistry, 2006, 281, 36783-36792.	1.6	16
85	E2F8 is an activator of heterotrimeric G proteins. FASEB Journal, 2006, 20, A935.	0.2	0
86	Geometric Magnetic Frustration inBa2Sn2Ga3ZnCr7O22: A Two-Dimensional Spinel Based Kagomé Lattice. Physical Review Letters, 2001, 86, 894-897.	2.9	115